SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jaybe3/23/2016 8:05:40 AM
   of 4474
 
Pona for lung cancer?...UK group finds 1-2% of NSCLC with ABL1 mutations...

"Here, we identify somatically mutated ABL1 as a novel driver in lung cancer, where cells with ABL1 mutations are sensitive to ABL1 inhibi- tors, imatinib and dasatinib."

"Since approximately 1–2% of patients with lung adenocarcinoma harbor ABL1 mutations, dasatinib or imatinib could represent a treat- ment option for 8,500–17,000 patients with lung cancer globally."

embomolmed.embopress.org
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News